Xintela reports positive preclinical results in cancer project
Xintela AB (publ) today announces an update of the company’s projects in regenerative medicine and cancer. All projects are developing in a positive way. New results from the cancer project show that Xintela’s targeting antibody kills glioblastoma cells both in cell studies and in an animal model. Significant progress in the treatment of the brain […]
Xintela’s stem cells show positive treatment effects on cartilage damage in horse study
Xintela AB (publ), announces today that the company’s selected stem cells have beneficial effects on joint cartilage and underlying bone in post- traumatic osteoarthritis, based on additional analysis of the company’s horse study and the final report from Cornell University, Ithaca, New York. The results are very promising for Xintela’s development of stem cell therapy […]
Newsletter December
The year 2016 has been both intensive and exciting and during which Xintela has experienced strong growth. Together with our current progress in regenerative medicine and cancer, we have also strengthened the company’s structure and resources. We conducted an oversubscribed rights issue and listed the company on Nasdaq First North, in addition to making several […]
Xintela reports positive results from completed horse study
Xintela AB (publ), announces today that the company’s completed horse study met its primary endpoint, demonstrating that Xintela’s stem cells are safe. Xintela can now take the next step in the development of an effective, safe stem cell product for the treatment of cartilage damage and osteoarthritis. “We are very pleased to report a positive […]
Xintela’s Focus in the Cancer Arena
XINMARK is Xintela’s patented integrin technology platform that is being developed with the aim of commercialising innovative and improved treatments in two main areas: regenerative medicine and cancer. Within the cancer arena, Xintela’s research focuses on glioblastoma, an aggressive brain tumour, and this newsletter provides an update on our progress to date.
Focus on commercial development
As our projects progress, it is important to ensure that we have the right competencies to take them towards commercialisation. We are therefore delighted to start the Autumn with two new employees who will strengthen the company’s commercial team. Lina Boreson, with extensive experience from the pharmaceutical industry as, amongst other roles, Head of Marketing, […]
Preparing for an exciting Autumn
Swedish Summer is over and, at Xintela, we are preparing for an exciting Autumn. Since our listing in the Spring, the company has developed in a very positive way and we are on track with the milestones we have set. The purpose of our newsletter is to provide a better understanding of Xintela’s operations, to […]
Xintela recruits Rickard Mosell as Head of Business Development
On 12 September 2016, Xintela announces that Rickard Mosell has been recruited as Head of Business Development from October 1, 2016. Rickard Mosell will leave his current position as CEO of Ideon Innovation and will be responsible for Xintela’s business development and financing. Rickard Mosell will also be a member of Xintela’s management team. Rickard […]
Xintela receives 1,5 MSEK in dispute settlement
Xintela today announces that it has settled a dispute and will receive 1,500,000 Swedish Crowns in compensation. The background to the dispute is that the counter party, who had an assignment from Xintela to validate one of the company’s patents, missed the deadline for validation with the consequence that the patent was not validated in […]
Newsletter No.1
Click here to read the newsletter. Welcome to Xintela’s newsletter Since our listing on First North in March 2016, Xintela has had an intense period and we have been working at a high tempo with our ongoing projects. In order to keep our investors and other stakeholders informed about the company and our development, we […]
